145 related articles for article (PubMed ID: 32034760)
1. Interrupting tocilizumab therapy-induced psoriasis-like eruption in a patient with rheumatoid arthritis and Crohn's disease.
Saito Y; Hayashi S; Gonmori T; Hamasaki Y; Igawa K
Int J Dermatol; 2020 May; 59(5):e159-e160. PubMed ID: 32034760
[No Abstract] [Full Text] [Related]
2. Adalimumab drug survival in patients with psoriasis, Crohn's disease, and rheumatoid arthritis: Relevant differences using the same treatment.
van den Reek JM; Pijls PA; Tummers M; van Riel PC; Kievit W; Hoentjen F; de Jong EM
J Am Acad Dermatol; 2016 Jan; 74(1):177-9. PubMed ID: 26702800
[No Abstract] [Full Text] [Related]
3. Blockade of interleukin 6 signaling induces marked neutropenia in patients with rheumatoid arthritis.
Nakamura I; Omata Y; Naito M; Ito K
J Rheumatol; 2009 Feb; 36(2):459-60. PubMed ID: 19208585
[No Abstract] [Full Text] [Related]
4. Clinical studies in patients with Castleman's disease, Crohn's disease, and rheumatoid arthritis in Japan.
Nishimoto N
Clin Rev Allergy Immunol; 2005 Jun; 28(3):221-30. PubMed ID: 16129906
[TBL] [Abstract][Full Text] [Related]
5. Tocilizumab-induced psoriasis-like eruption resolved by shortening the dose interval in a patient with rheumatoid arthritis: a case-based review.
Hayakawa M; Izumi K; Higashida-Konishi M; Ushikubo M; Tsukamoto M; Akiya K; Araki K; Oshima H
Rheumatol Int; 2019 Jan; 39(1):161-166. PubMed ID: 30357484
[TBL] [Abstract][Full Text] [Related]
6. Psoriasis onset with tocilizumab treatment for rheumatoid arthritis.
Wendling D; Letho-Gyselinck H; Guillot X; Prati C
J Rheumatol; 2012 Mar; 39(3):657. PubMed ID: 22383356
[No Abstract] [Full Text] [Related]
7. Tocilizumab.
Venkiteshwaran A
MAbs; 2009; 1(5):432-8. PubMed ID: 20065633
[TBL] [Abstract][Full Text] [Related]
8. Perioperative Management of Biologic and Immunosuppressive Medications in Patients With Crohn's Disease.
Lightner AL
Dis Colon Rectum; 2018 Apr; 61(4):428-431. PubMed ID: 29521822
[No Abstract] [Full Text] [Related]
9. The blockade of IL-6 signaling in rational drug design.
Adachi Y; Yoshio-Hoshino N; Nishimoto N
Curr Pharm Des; 2008; 14(12):1217-24. PubMed ID: 18473869
[TBL] [Abstract][Full Text] [Related]
10. [Use of adalimumab in a patient with Crohn's disease and extensive generalised psoriasis who achieved complete remission of both conditions].
Piqueras M; Monfort D; Pol MA; Galter S; Modolell I; Ortiz J; Boadas J
Gastroenterol Hepatol; 2013; 36(6):396-9. PubMed ID: 23587662
[No Abstract] [Full Text] [Related]
11. Effect of IL-17 receptor A blockade with brodalumab in inflammatory diseases.
Nirula A; Nilsen J; Klekotka P; Kricorian G; Erondu N; Towne JE; Russell CB; Martin DA; Budelsky AL
Rheumatology (Oxford); 2016 Dec; 55(suppl 2):ii43-ii55. PubMed ID: 27856660
[TBL] [Abstract][Full Text] [Related]
12. A Case Report of Successful Treatment of Crohn's Disease and Psoriasis With Guselkumab.
Grossberg LB
Inflamm Bowel Dis; 2019 Jun; 25(7):e84. PubMed ID: 30863855
[No Abstract] [Full Text] [Related]
13. IL-36γ sustains a proinflammatory self-amplifying loop with IL-17C in anti-TNF-induced psoriasiform skin lesions of patients with Crohn's disease.
Friedrich M; Tillack C; Wollenberg A; Schauber J; Brand S
Inflamm Bowel Dis; 2014 Nov; 20(11):1891-901. PubMed ID: 25299544
[TBL] [Abstract][Full Text] [Related]
14. Letter: Effectiveness of split-dose certolizumab pegol for Crohn's disease.
Kane SV; Neis B; Becker BD; Bruining D; Faubion WA; Kisiel J; Loftus EV; Pardi D; Raffals L; Schroeder K; Tremaine WJ
Aliment Pharmacol Ther; 2013 Dec; 38(11-12):1412. PubMed ID: 24206378
[No Abstract] [Full Text] [Related]
15. Tocilizumab-induced pustular drug eruption.
Mori T; Yamamoto T
Int J Rheum Dis; 2017 Nov; 20(11):1776-1777. PubMed ID: 26218136
[No Abstract] [Full Text] [Related]
16. Distinct expression of interleukin (IL)-36α, β and γ, their antagonist IL-36Ra and IL-38 in psoriasis, rheumatoid arthritis and Crohn's disease.
Boutet MA; Bart G; Penhoat M; Amiaud J; Brulin B; Charrier C; Morel F; Lecron JC; Rolli-Derkinderen M; Bourreille A; Vigne S; Gabay C; Palmer G; Le Goff B; Blanchard F
Clin Exp Immunol; 2016 May; 184(2):159-73. PubMed ID: 26701127
[TBL] [Abstract][Full Text] [Related]
17. Drug eruption induced by IL-6 receptor inhibitor tocilizumab.
Yoshiki R; Nakamura M; Tokura Y
J Eur Acad Dermatol Venereol; 2010 Apr; 24(4):495-6. PubMed ID: 19754658
[No Abstract] [Full Text] [Related]
18. [Immunosuppression may mask severe infection. Septic arthritis in tocilizumab treatment yielded only modest acute-phase reaction].
Ljung L; Smeds J; Persson G; Jirlén L; Toolanen G
Lakartidningen; 2012 Sep 19-26; 109(38):1678-9. PubMed ID: 23094399
[No Abstract] [Full Text] [Related]
19. A Unique Infusion Reaction to Vedolizumab in a Patient With Crohn's Disease.
Gold SL; Magro C; Scherl E
Gastroenterology; 2018 Oct; 155(4):981-982. PubMed ID: 29614303
[No Abstract] [Full Text] [Related]
20. Crohn's disease diagnosis during adalimumab treatment.
Fernández Salazar L; Barrio Andrés J; González Hernández JM
Scand J Gastroenterol; 2013 Feb; 48(2):254-5. PubMed ID: 23061423
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
